Methods: Fetal aortic PP was estimated by using pulse wave velocity (PWV) and blood flow velocity at fetal descending aorta. Each motion of the proximal and distal border of the lumen of fetal descending aorta was analysed using Phased Tracking. The velocities were analysed at each point, and the time delay between them was measured. PWV was obtained by dividing the distance between the analysed points by the time delay of the pulse wave. In the Water-Hammer equation, PP is given as follows: PP=ρ×U×PWV, where ρ is blood density, U is blood velocity. The blood velocity was measured by ultrasound with pulse Doppler. We chose an artificial placenta (AP) as a fetus model. Premature lambs (90-137 days; term=147d) were used. Immediately after delivery of the fetuses(n=3), the umbilical vessels were cannulated and connected to the pumpless AP and the carotid catheter was inserted to measure aortic BP. We compared the PPs estimated by using the ultrasound with the PPs measured by the carotid catheter. Results: Median estimated PP by the ultrasound was 17.4mmHg in comparison to 18.0mmHg by the carotid catheter. There was a significant correlation between the PP estimated by using the ultrasound and the PP measured by using the carotid catheter (R 2 =0.95.p<0.01) (figure1).
Supporting information can be found in the online version of this abstract Objectives: PAH is a life-threatening vasculopathy of the pulmonary arteries. In spite of new treatments, PAH poses serious risks for pregnant women. Current guidelines recommend termination of pregnancy secondary to high mortality. MT has not previously been reported in cases of PAH and this is the first report of MT in early gestation.
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Methods:
The patient was 30 year-old G2P1 referred at 6 1/7 weeks of pregnancy complicated with PAH. The EKG showed right axis deviation and an echo with pulmonary artery pressure (PAP) of 86 mmHg. Ultrasound (US) showed a singleton pregnancy with fetal pole (6-0/7 weeks), gestational sac and cardiac activity. There were elevated BNP and a history of C/S. A plan devised use of MT due to ease of use, proper gestational age (< 63 days) and electing the least aggressive anesthetic and surgical intervention. To limit blood loss, suction and curettage (S&C) was advocated 6 hours after misoprostol administration. The protocol called for 600mg of mifepristone orally (a progesterone receptor antagonist) a day prior to S&C and 600mg of oral misoprostol (E1 agonist), a PA dilator on the day of S&C. Within 3 hours following misoprostol, the patient started cramping. Five hours after misoprostol, her cervix was 1cm dilated with minimal POC expelled. At 6 hours she underwent S&C under sedation (4mg of versed, 200mcg fentanyl and 8mg etomidate).
Results:
The PAP was 95 mmHg on day prior to S&C. Following mifepristone and misoprostol, the PAP decreased to 29 mmHg. MT allowed cervical dilatation and S&C under minimal to moderate sedation. US confirmed complete evacuation of the uterus.
Conclusions: MT can be successfully implemented in cases of PAH. In this case there was an associated decrease in PAP (95 to 29 mmHg). Both general and regional anesthesia were avoided and S&C were performed under sedation without significant fluid overload or significant blood loss. 
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